# A Study of QLS2404 Injection in Healthy Participants and Participants With Rheumatic Autoimmune Diseases

> **NCT07751315** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 64 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus
- Primary Sjögren's Syndrome

## Interventions

- **DRUG:** Ia:QLS2404 very low dose
- **DRUG:** Ia:QLS2404 low dose
- **DRUG:** Ia:QLS2404 middle dose
- **DRUG:** Ia:QLS2404 high dose
- **DRUG:** Ia:QLS2404 Max dose
- **DRUG:** Ib:QLS2404 low dose
- **DRUG:** Ib:QLS2404 middle dose
- **DRUG:** Ib:QLS2404 high dose

## Key facts

- **NCT ID:** NCT07751315
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-11
- **Primary completion:** 2027-11-07
- **Final completion:** 2028-06-30
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2026-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07751315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07751315, "A Study of QLS2404 Injection in Healthy Participants and Participants With Rheumatic Autoimmune Diseases". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07751315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*